
Berthold Schenkel, PhD
Advertisement
Berthold Schenkel, PhD, is head of technology group 1, CHBS, at Novartis Pharma AG
Articles by Berthold Schenkel, PhD

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
2
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
3
FAQ: What FDA’s Individualized Gene Editing Draft Guidance Means for Developers
4
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
5

